| Assessment Status | Assessment Process Complete |
| HTA ID | - |
| Drug | Migalastat |
| Brand | Galafold® |
| Indication | For the long term treatment of adult and adolescent patients 16 years and older with a confirmed diagnosis of Fabry disease and who have an amenable mutation. |
| Assessment Process | |
| Rapid review commissioned | 14/07/2016 |
| Rapid review completed | 18/08/2016 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
| Full submission received from Applicant | 03/01/2017 |
| NCPE assessment completed | 01/06/2017 |
| NCPE assessment outcome | Reimbursement Recommended |
The NCPE recommends reimbursement of Migalastat (Galafold®) subject to the continuing availability of a patient access scheme.
